Integrated protein quality-control pathways regulate free α-globin in murine β-thalassemia

Blood

Volumn 119, Issue 22, 2012, Pages 5265-5275

  Khandros, Eugene ^a   Thom, Christopher S ^a   D'Souza, Janine ^b   Weiss, Mitchell J ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLOBIN; PROTEASOME; TRANSCRIPTION FACTOR NRF1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHAGY; BETA THALASSEMIA; CELL PROTECTION; CONTROLLED STUDY; EMBRYO; ERYTHROID CELL; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN MODIFICATION; STRESS; UBIQUITINATION;

EID: 84861816666     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-12-397729     Document Type: Article

References (58)

1. Steinberg MH. Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management. 2nd Ed. Cambridge, United Kingdom: Cambridge University Press; 2009.
2. Khandros E, Weiss MJ. Protein quality control during erythropoiesis and hemoglobin synthesis. Hematol Oncol Clin North Am. 2010;24(6):1071-1088.
3. Ciechanover A, Brundin P. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron. 2003;40(2):427-446.
4. Ding W-X, Yin X-M. Sorting, recognition and activation of the misfolded protein degradation pathways through macroautophagy and the proteasome. Autophagy. 2008;4(2):141-150.
5. Jaeger PA, Wyss-Coray T. All-you-can-eat: autophagy in neurodegeneration and neuroprotection. Mol Neurodegener. 2009;4:16.
6. Wood WG, Stamatoyannopoulos G. Globin synthesis in fractionated normoblasts of beta-thalassemia heterozygotes. J Clin Invest. 1975;55(3):567-578.
7. Bank A, O'Donnell JV. Intracellular loss of free alpha chains in beta thalassemia. Nature. 1969; 222(5190):295-296.
8. Clegg JB, Weatherall DJ. Haemoglobin synthesis during erythroid maturation in beta-thalassaemia. Nat New Biol. 1972;240(101):190-192.
9. Kan YW, Nathan DG, Lodish HF. Equal synthesis of alpha- and beta-globin chains in erythroid precursors in heterozygous beta-thalassemia. J Clin Invest. 1972;51(7):1906-1909.
10. Braverman AS, Lester D. Evidence for increased proteolysis in intact beta thalassemia erythroid cells. Hemoglobin. 1981;5(6):549-564.
11. Loukopoulos D, Karoulias A, Fessas P. Proteolysis in thalassemia: studies with protease inhibitors. Ann N Y Acad Sci. 1980;344:323-335.
12. Shaeffer JR. Turnover of excess hemoglobin alpha chains in beta-thalassemic cells is ATP-dependent. J Biol Chem. 1983;258(21):13172-13177.
13. Vettore L, De Matteis MC, Di Iorio EE, Winterhalter KH. Erythrocytic proteases: preferential degradation of alpha hemoglobin chains. Acta Haematol. 1983;70(1):35-42.
14. Shaeffer JR. ATP-dependent proteolysis of hemoglobin alpha chains in beta-thalassemic hemolysates is ubiquitin-dependent. J Biol Chem. 1988;263(27):13663-13669.
15. Ciehanover A, Hod Y, Hershko A. A heat-stable polypeptide component of an ATP-dependent proteolytic system from reticulocytes. Biochem Biophys Res Commun. 1978;81(4):1100-1105.
16. Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell. 2010;140(3):313-326.
17. Kang YA, Sanalkumar R, O'Geen H, et al. Autophagy driven by a master regulator of hematopoiesis. Mol Cell Biol. 2012;32(1):226-239.
18. Schweers RL, Zhang J, Randall MS, et al. NIX is required for programmed mitochondrial clearance during reticulocyte maturation. Proc Natl Acad Sci U S A. 2007;104(49):19500-19505.
19. Zhang J, Ney PA. Autophagy-dependent and -independent mechanisms of mitochondrial clearance during reticulocyte maturation. Autophagy. 2009;5(7):1064-1065.
20. Sandoval H, Thiagarajan P, Dasgupta SK, et al. Essential role for Nix in autophagic maturation of erythroid cells. Nature. 2008;454(7201):232-235.
21. Wickramasinghe SN, Bush V. Observations on the ultrastructure of erythropoietic cells and reticulum cells in the bone marrow of patients with homozygous beta-thalassaemia. Br J Haematol. 1975;30(4):395-399.
22. Wickramasinghe SN, Hughes M. Ultrastructural studies of erythropoiesis in beta-thalassaemia trait. Br J Haematol. 1980;46(3):401-407.
23. Lithanatudom P, Wannatung T, Leecharoenkiat A, Svasti S, Fucharoen S, Smith DR. Enhanced activation of autophagy in beta-thalassemia/Hb E erythroblasts during erythropoiesis. Ann Hematol. 2011;90(7):747-758.
24. Hidvegi T, Ewing M, Hale P, et al. An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science. 2010;329(5988):229-232.
25. Li J, Horak KM, Su H, Sanbe A, Robbins J, Wang X. Enhancement of proteasomal function protects against cardiac proteinopathy and ischemia/reperfusion injury in mice. J Clin Invest. 2011;121(9):3689-3700.
26. Yang B, Kirby S, Lewis J, Detloff PJ, Maeda N, Smithies O. A mouse model for beta 0-thalassemia. Proc Natl Acad Sci U S A. 1995;92(25):11608-11612.
27. Yu X, Kong Y, Dore LC, et al. An erythroid chaperone that facilitates folding of alpha-globin subunits for hemoglobin synthesis. J Clin Invest. 2007;117(7):1856-1865.
28. England SJ, McGrath KE, Frame JM, Palis J. Immature erythroblasts with extensive ex vivo selfrenewal capacity emerge from the early mammalian fetus. Blood. 2011;117(9):2708-2717.
29. Verdoes M, Florea BI, Menendez-Benito V, et al. A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo. Chem Biol. 2006;13(11):1217-1226.
30. Kong Y, Zhou S, Kihm AJ, et al. Loss of alpha-hemoglobin- stabilizing protein impairs erythropoiesis and exacerbates beta-thalassemia. J Clin Invest. 2004;114(10):1457-1466.
31. Gardenghi S, Ramos P, Marongiu MF, et al. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in beta-thalassemic mice. J Clin Invest. 2010;120(12):4466-4477.
32. Liu Y, Pop R, Sadegh C, Brugnara C, Haase VH, Socolovsky M. Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo. Blood. 2006;108(1):123-133.
33. Gill FM, Schwartz E. Free alpha-globin pool in human bone marrow. J Clin Invest. 1973;52(12):3057-3063.
34. Bjørkøy G, Lamark T, Brech A, et al. p62/ SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin- induced cell death. J Cell Biol. 2005;171(4):603-614.
35. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-15550.
36. Ohtsuji M, Katsuoka F, Kobayashi A, Aburatani H, Hayes JD, Yamamoto M. Nrf1 and Nrf2 play distinct roles in activation of antioxidant response element-dependent genes. J Biol Chem. 2008;283(48):33554-33562.
37. Radhakrishnan SK, Lee CS, Young P, Beskow A, Chan JY, Deshaies RJ. Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells. Mol Cell. 2010;38(1):17-28.
38. Steffen J, Seeger M, Koch A, Krüger E. Proteasomal degradation is transcriptionally controlled by TCF11 via an ERAD-dependent feedback loop. Mol Cell. 2010;40(1):147-158.
39. Zhang Y, Talalay P, Cho CG, Posner GH. A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc Natl Acad Sci U S A. 1992;89(6):2399-2403.
40. Kim HJ, Joo HJ, Kim YH, et al. Systemic analysis of heat shock response induced by heat shock and a proteasome inhibitor MG132. PLoS One. 2011;6(6):e20252.
41. Testa U. Proteasome inhibitors in cancer therapy. Curr Drug Targets. 2009;10(10):968-981.
42. Chen CY, Pajak L, Tamburlin J, Bofinger D, Koury ST. The effect of proteasome inhibitors on mammalian erythroid terminal differentiation. Exp Hematol. 2002;30(7):634-639.
43. Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist. 2003;8(6):508-513.
44. Luker GD, Pica CM, Song J, Luker KE, Piwnica-Worms D. Imaging 26S proteasome activity and inhibition in living mice. Nat Med. 2003;9(7):969-973.
45. Fessas P. Inclusions of hemoglobin erythroblasts and erythrocytes of thalassemia. Blood. 1963;21:21-32.
46. Weatherall DJ, Clegg JB, Naughton MA. Globin synthesis in thalassaemia: an in vitro study. Nature. 1965;208(5015):1061-1065.
47. Nathan DG, Gunn RB. Thalassemia: the consequences of unbalanced hemoglobin synthesis. Am J Med. 1966;41(5):815-830.
48. Bank A. Hemoglobin synthesis in beta-thalassemia: the properties of the free alpha-chains. J Clin Invest. 1968;47(4):860-866.
49. Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol. 2000;10(12):524-530.
50. Wickramasinghe SN, Lee MJ. Evidence that the ubiquitin proteolytic pathway is involved in the degradation of precipitated globin chains in thalassaemia. Br J Haematol. 1998;101(2):245-250.
51. Kapeta S, Chondrogianni N, Gonos ES. Nuclear erythroid factor 2-mediated proteasome activation delays senescence in human fibroblasts. J Biol Chem. 2010;285(11):8171-8184.
52. Kwak M-K, Wakabayashi N, Greenlaw JL, Yamamoto M, Kensler TW. Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway. Mol Cell Biol. 2003;23(23):8786-8794.
53. Lee CS, Lee C, Hu T, et al. Loss of nuclear factor E2-related factor 1 in the brain leads to dysregulation of proteasome gene expression and neurodegeneration. Proc Natl Acad Sci U S A. 2011; 108(20):8408-8413.
54. Chan JY, Kwong M, Lu R, et al. Targeted disruption of the ubiquitous CNC-bZIP transcription factor, Nrf-1, results in anemia and embryonic lethality in mice. EMBO J. 1998;17(6):1779-1787.
55. Dy GK, Thomas JP, Wilding G, et al. A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. Clin Cancer Res. 2005;11(9):3410-3416.
56. Weiss MJ, Dos Santos CO. Chaperoning erythropoiesis. Blood. 2009;113(10):2136-2144.
57. Wu WK, Sakamoto KM, Milani M, et al. Macroautophagy modulates cellular response to proteasome inhibitors in cancer therapy. Drug Resist Updat. 2010;13(3):87-92.
58. Zhu K, Dunner K Jr, McConkey DJ. Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells. Oncogene. 2010;29(3):451-462.